Pre-cluster symptoms in a Taiwanese cohort of cluster headache: symptom profiles and clinical predictions

• Published in: Journal of headache and pain 2024-10, Vol.25 (1), p.174-12, Article 174
• Main Authors: Wu, Jr-Wei, Chen, Shu-Ting, Wang, Yen-Feng, Chen, Shih-Pin, Tseng, Shin-Yi, Kuo, Yih-Shiuan, Chen, Wei-Ta, Chiang, Chia-Chun, Wang, Shuu-Jiun
• Format: Article
• Language: English
• Subjects: Adult; Cluster headache; Cluster Headache - diagnosis; Cluster Headache - drug therapy; Cluster Headache - epidemiology; Cross-Sectional Studies; Female; Head and neck; Headache; Headaches; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Neck pain; Neurology; Pain; Pain Medicine; Patients; Pre-cluster symptoms; Prevalence; Prodromal Symptoms; Prospective Studies; Skull; Sleep; Taiwan - epidemiology; Verapamil; Verapamil - therapeutic use
• ISSN: 1129-2377; 1129-2369; 1129-2377
• DOI: 10.1186/s10194-024-01862-8

Background Pre-cluster symptoms (PCSs) are symptoms preceding cluster bouts and might have implications for the treatment of cluster headache (CH). This study investigated the prevalence of PCSs, and their utility in predicting upcoming bouts as well as the associations with therapeutic efficacy. Methods We prospectively collected data from patients with CH. Each patient received a structured interview and completed questionnaire surveys during CH bouts. In sub-study 1, we cross-sectionally analyzed the prevalence, symptomatology, and predictability of upcoming bouts. Overall, 34 PCSs, divided into seven categories, were queried, including head and neck pain, cranial autonomic symptoms, restlessness, fatigue or mood changes, sleep alterations, constitutional symptoms, and generalized pain. In sub-study 2, we recorded the weekly frequency of CH attacks after the initiation of verapamil concurrently with a 14-day transitional therapy based on the patients’ headache diary. A responder to verapamil was defined as a patient who have a reduction from baseline of at least 50% in the weekly frequency of CH attacks 4 weeks after the initiation of verapamil. Results A total of 168 CH patients (women/men: 39/129) completed the study. In sub-study 1, we found 149 (88.7%) experienced PCSs, with a median of 24 (IQR 18 to 72) hours before the bouts. Up to 57.7% of patients with PCS reported that they could predict upcoming bouts. Among the seven categories of PCSs, head and neck pain was the most common (81.0%) and was associated with a higher predictability of upcoming bouts (odds ratio [OR] = 4.0; 95% confidence interval [CI] 1.7–9.6). In sub-study 2, we found two categories of PCSs were associated with the response to verapamil: sleep alteration (OR = 2.5 [95% CI = 1.3–4.8], p  = 0.004) and ≥ 1 cranial autonomic symptoms (OR = 2.7 [95% CI = 1.4–5.1], p  = 0.003). Conclusion PCSs were very common in CH and could be used to predict upcoming bouts. Different symptom categories of PCSs may have different clinical implications.